Feed AKBA
AK

Akebia Therapeutics, Inc. AKBA · NASDAQ

$0.67 -3.67% (-$0.03)

Market cap
$186.6M
Enterprise value
$85.0M
P/E
-
Forward P/E
-
PEG
-
P/S
0.9x
P/FCF
4.6x
EV/EBITDA
-
ROIC
-7.5%
Bruto marža
79.5%
Neto marža
-13.5%
Dividend yield
-
Payout ratio
-
Neto dolg/EBITDA
-
Beta
0.24
Free float
97.3%

O podjetju

Akebia Therapeutics, Inc. (AKBA) is an American biotechnology company focused on developing medications for the treatment of kidney-related diseases and other medical conditions. The company is dedicated to discovering and advancing novel therapeutic approaches, including drugs for anemia associated with chronic kidney disease. Akebia Therapeutics aims to innovate and provide new treatment options for patients with serious health issues. The biotechnology industry can be influenced by regulatory approval processes and developmental milestones. Akebia Therapeutics, Inc. (AKBA) shares could be an intriguing choice for investors interested in the healthcare sector and biotechnology.

Sector

Healthcare

Industry

Biotechnology

CEO

John Butler

Employees

194

Headquarters

Waltham

Vrednotenje

Je današnja cena primerna?

Rast in ocene

Ali podjetje raste in kaj sledi?

Donosnost in kakovost

Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?

Finančno zdravje

Ali zmore svoj dolg?

Kapital in dividende

Kaj podjetje počne z zasluženim denarjem?

Analitiki

Kaj menijo strokovnjaki in ali se to spreminja?

Lastniki in insajderji

Kdo ima delnice in kaj počne vodstvo?

Segmenti

Kateri del podjetja raste?

Primerjava s konkurenco

Kako se primerja s podobnimi podjetji?

Cena in tveganje

Kako se delnica obnaša?

Izkazi

Vse številke

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.